clinical trial · NCT03859869
A Study of Creon (Pancrelipase) in Resected and Non-resected Pancreatic Cancer Participants With Exocrine Pancreatic Insufficiency (EPI)
AbbVie·phase4·terminated·n = 1
Exocrine Pancreatic Insufficiency (EPI)PancrelipasePlacebo
brief summary
This is a study in participants with Exocrine Pancreatic Insufficiency (EPI) due to pancreatic cancer. This study will include resected participants who are post pancreatic cancer surgery, and an additional cohort in non-resected participants.
started
Feb 25, 2020
primary completion
Mar 23, 2022
completion
Mar 23, 2022
last updated
Jun 5, 2023
official title
Creon (Pancrelipase) Therapy for Subjects With Exocrine Pancreatic Insufficiency (EPI) Due to Pancreatic Cancer: A Double-blind, Randomized, Parallel Design With 2 Dose Cohorts of Pancrelipase in Resected Pancreatic Cancer Subjects and an Open-label Single Dose Cohort in Non-resected Pancreatic Cancer Subjects
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol